The firm has also received CE mark approval for the system, which was first acquired by Chirayu Medical College and Hospital (CMCH) in Bhopal, India.

CMCH owner Dr Ajay Goenka said: "We chose VitalBeam because we wanted something with the advantages of the TrueBeam platform that would enable us to go beyond basic intensity-modulated radiotherapy."

The VitalBeam platform is said to integrate Varian’s multiple innovations to improve the precision, safety and speed of treatment on its TrueBeam radiotherapy system.

According to CMCH physician Dr T. P. Sahoo, the clinical team at the hospital will use the VitalBeam system to treat patients with tumors in vital locations where toxicity to healthy tissues must be minimized.

Varian’s oncology systems business president Kolleen Kennedy said: "Our goal, with this platform, was to help increase access to quality cancer care around the world.

"We are gratified to work with institutions like the Chirayu Medical College in bringing advanced, image-guided radiotherapy to more cancer patients."

In July 2014, Varian received 510(k) approval from the US Food and Drug Administration for the Calypso soft tissue Beacon transponder, which was developed to enhance the precision of radiotherapy and radiosurgery treatments for cancer.

Varian offers comprehensive solutions for radiotherapy, radiosurgery, proton therapy and brachytherapy, as well as provides informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices.

It also supplies X-ray imaging components, including tubes, digital detectors, and image processing software and workstations for use in medical, scientific, and industrial settings, as well as for security and non-destructive testing.

Image: Varian’s VitalBeam radiotherapy treatment platform. Photo: courtesy of Varian Medical Systems, Inc.